New research has identified a protein that could serve as both a biomarker and therapeutic target to weaken stem-like cancer ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

Druggable phosphatases in cancer and immune cells, with examples of their corresponding drugs. Structures of allosteric inhibitors targeting PP2A, PRL3, DUSP1/6, and SHP2 in cancer cells (left).

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

Scientists at The Wistar Institute and ChristianaCare’s Helen F. Graham Cancer Center & Research Institute have uncovered a ...

Learn more about a new experimental procedure that uses cancer cells’ DNA repair system against itself to make drug-resistant ...

Children with lesions on the top or back of the tongue often face significant challenges with eating and speaking. With ...

Beyond weight loss, GLP-1s may offer a "two-for-one" benefit by protecting heart health, which is the leading cause of ...

Scientists at The Wistar Institute and clinical researchers from ChristianaCare’s Helen F. Graham Cancer Center & Research ...

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

Colorectal tumors that underwent somatic next-generation sequencing (NGS) for 154-168 genes in an in-house laboratory between 2015 and 2022 were retrospectively identified. Microsatellite instability ...

Lifestyle and chemical exposures-from diet to pesticides, herbicides-are increasingly linked to rising colon cancer rates in ...